rs200069860
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 0P and 11B. BP4_ModerateBP6BS1BS2
The NM_001005242.3(PKP2):c.964G>T(p.Gly322Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000551 in 1,614,134 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001005242.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000256 AC: 39AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000639 AC: 16AN: 250526Hom.: 0 AF XY: 0.0000590 AC XY: 8AN XY: 135494
GnomAD4 exome AF: 0.0000342 AC: 50AN: 1461834Hom.: 0 Cov.: 33 AF XY: 0.0000330 AC XY: 24AN XY: 727214
GnomAD4 genome AF: 0.000256 AC: 39AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74470
ClinVar
Submissions by phenotype
not specified Uncertain:1Benign:1
- -
Variant summary: PKP2 c.964G>T (p.Gly322Cys) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.5e-05 in 1614134 control chromosomes, predominantly at a frequency of 0.0011 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is at the estimated maximal expected allele frequency for a pathogenic variant in PKP2 causing Cardiomyopathy phenotype (0.0011), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.964G>T has been reported in the literature as a VUS in settings of multigene panel testing in at-least one individual with unexplained cardiac arrest and in another individual with hypertrophic cardiomyopathy (HCM) (example, Mellor_2017, Lopes_2015).. These report(s) do not provide unequivocal conclusions about association of the variant with Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 25351510, 28600387). Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified as likely benign (n=5) and VUS (n=2). Based on the evidence outlined above, the variant was classified as likely benign. -
Ventricular fibrillation Uncertain:1
- -
Arrhythmogenic right ventricular dysplasia 9 Benign:1
- -
Arrhythmogenic right ventricular cardiomyopathy Benign:1
- -
Cardiomyopathy Benign:1
- -
PKP2-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
not provided Benign:1
- -
Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Amyloidosis, hereditary systemic 1 Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at